The debate between GE and Bracco over GE’s marketing of its Visipaque contrast agent continues despite a U.S. District Court finding that GE used false advertising to win sales for the x-ray contrast agent.
The debate between GE and Bracco over GE's marketing of its Visipaque contrast agent continues despite a U.S. District Court finding that GE used false advertising to win sales for the x-ray contrast agent.
GE Healthcare is permanently enjoined from making such claims and must pay Bracco damages of $11.4 million. The ruling is a consequence of litigation begun six years ago by Bracco and settled in a New Jersey court last week. In the days after the decision, however, executives at the two companies gave markedly different interpretations of the significance of the case and the court's findings.
"The court found that there were some specific extrapolations that led to false advertising," said Eric Cantor, head of medical and professional affairs for GE Medical Diagnostics. "But the court in many ways found that the majority of GE Healthcare's messages were in fact true and were properly relied upon and were based on reliable scientific studies to support them."
Bracco chief executive Carlo Medici asserted that GE's false ads allegedly "generated hundreds of millions of dollars in profits for them." But how badly those ads hurt Bracco is difficult to judge. Medici, president and CEO of Bracco Diagnostics, noted that Isovue improved its position in the market from 2003 to the present. Thanks to the court ruling, it stands to gain even more.
"We now have 34% market share; one-third of the procedures in the U.S. use our product," he said. "Isovue is the number one brand in the U.S., and so we believe that our strategy in the marketplace has been successful, and now it is going to be confirmed and strengthened by this court's ruling."
For more information from the Diagnostic Imaging and SearchMedica archives:
X-ray contrast case: Bracco wins $11.4 million in damages from GE
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.